Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Gcbr,from the 8k filing it looks like ownership interest will become effective as of our purchase of initial 2,157,000 shares so that the bill of $25 Million does not have to be paid in full to have ownership. But again i could be wrong.
Gcbr,thanks again but allow me to share one more time on this issue,please. If we dont own Biofrontera untill the $25 Million is paid then merging/Nasdaq Via Biofrontera would not happen untill the bill is paid over the 2 year period. BUT BUT if Dnap should come out with a FDA approval on say Ovanome and or Statnome long before the bill is paid then why would we need Biofrontera to get on the nasdaq and why would we merg with them at that point we would have our pick of who to merg with. YES or no Once FDA approval comes our way all the Big Boys rush in both on Market trading and in making deals, Big deals,yes or am i off on this.
Gcbr,I dont understand it very well either.And am very happy for your help on this matter.It makes a little more sence to me now,thanks.But the $25 Million was to be payed over a 2 year period.If we merg i think it will happen soon before the full amount is paid.Doesent this save us money and shares or am i wrong - we can not merg untill the full amount of the $25 Million is paid ?????
I have a question to pose - If Biofrontera goes public to get on say the Nasdaq and we down the road merg with Biofrontera then we would be both one and the same comp. 1} we to then would end up on Nasdaq and the Bal. of the $20 million would go to us. Right I mean we would not have to make a million dollar payment every month to Biofrontera we could just pocket the money for our New and Bigger comp. and the 20 Million pluss the 35 million would go to us,thats 55 Million. YES or No. any thoughts
Oh come on Miss Scarlet follow me down the road of sin and tell me something else witty good job we dont want you serving the wrong master now do we.
It is you who love frogs - you said it yourself.
You madam are from the pond and most likely wont ever get out.
Ya,Ha thats all you can get Frogs, Ha
Just bad air !!!
Its very SIMPLE its frog's personality.He's this way with us, with the very few friends he has,with co-workers with family.Its his personality, therefore beyond his control, BUT not ours, tos him he will not change---I repeat He will not change !!!
Gcbr,this one you posted is From our guys at Stanford.Getting back to the Biometrics Council once again with Ron Kimmel and Margaret L. Johnson and the Bronstein Twins and their 3D scanner.Stanford is not just involved with Forensics but personalized medicine as well. Stanford plays a big roll here we should see something come up at some point about Dnap and Stanford
Gcbr,there are 2 things needed IMHO that cause a comp. to fly.1} is corporate power, the other is, 2} Political power and Dnap has both on their side. With all these pr's coming out on personalized medicine its easy to see someone is starting to pull some strings. A kind of preparation is taking place around the country. Just another sign something is about to blow.
Look adsx took about 1 year for FDA approval on their medical Devise {chip} The FDA says on their web site it takes about a Year for approval on medical devise's,RIGHT.What do we know, clinical trials ended with University of Miami/Jackson Memorial Medical center, 3 years completed or was it 4, Dec.2003 and we know there were other Hospitals in Fl. that were doing trials right along with UOM.So a year from then would put us around Dec. 2004 and Tony said FDA approval would be submitted in Mid 2004 so somewhere between Nov.2004 and July 2005 we could have FDA approval. I tend to think Dnap does not want to pay out a Million a Mo. for the Next 7 or 8 Months without revenue so i think we may have FDA approval or a merg by Dec.2004 if not sooner.
Bigdrive,It has always been my view that if i wanted to know if a system will work it always pays to check first the integrity of the system it self.And then one can tell how long something will last and just how far it will go. Dnap has many strong joints and connections and it is developing support systems all over.To know for sure would require a inspection BUT if you dont know what to look for than you will not feel confortable with your own results.I have great confidence in my self and my system of inspection.Dnap will do fine.
DRCAL,dont ya just Love it.$$$$
Chucker, I think it said in the 8k filing First payment due 20 days after the effectiveness of the registration is confirmed.
Chucker, yes, until after the effectiveness of this registration. I think the key word here is untill after the EFFECTIVENESS - than the clock ticks for the first payment,once received than were good to go as partners.
If Biofrontera is a Partner with one of the companys below than wouldn't that make us a partner with them as well ?? $$$$
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
Customers and Partners with Biofrontera - Advalytix AG, Bayer Cropscience AG, Evotec OAI AG, Janssen Pharmaceutica NV (J&J-Group), Kiadis BV, Merck KGaA, Schering AG, Schwarz Biosciences GmbH, Universities and other research institutions
I like this one -
In connection with the Biofrontera Agreement, Biofrontera Pharmaceutical GmbH, a wholly-owned subsidiary of Biofrontera, and we have entered into a joint venture framework agreement. The framework agreement outlines the procedures pursuant to which Biofrontera and we intend to exchange proprietary information and enter into commercial development activities with respect to projects that one or the other party currently has under development.Thats theirs is ours !!!
Remember the Biofrontera deal MUST be reg. with the sec. before Feb.6 2005 or its over.So if something will happen its going to happen before Feb.,my guess is Jan. the deal will go through. and maybe in Feb or march FDA approval.It better be so for Dnap to pay out 1 Million a Month to the Bank. ---$$$$$$$$$$$$$$$$$$$$
bigdrive, Biofrontera has working agreements and contracts with Kiadis NOTHING has changed except they will not merg for now.But they are still working togeather.You are not reading my post right or the press releases and filings because this info. is in there
Go into Oxford web site and you will find the partnership with Kiadis.
The Partner comes out of Kiadis and Oxford. And Biofrontera is working on projects with Kiadis who is partners with oxford. My feeling is we will merg with Kiadis down the road and if not our Mark will have been made with Oxford in any case.Either way we win.
Another Partner,it only gets better from here - http://www.oxfordbiomedica.co.uk
Why do you think, when Kiadis & Biofrontera were going to merge as Aliga, Johnson Matthey again shows up as a current investor {http://www.kiadis.com/kiadis/data/files/fact%20sheet%20aliga.pdf }And in Dnap's 8K filing and again in Biofrontera's web site year 2000 under PharmEco.
Bayer - BASF - Schering AG - NewLab Bio Quality AG - Johnson & Johnson {Janssen Pharmaceuticals} - Boehringer Ingelheim - Boerhringer Mannheim - Johnson Matthey Pharmaceuticals - PharmEco - IBM - Moffit - Affymetrix - Mayo - Stanford - Pen State - London School of Medicine And the list goes on and on Ba Hah ah ah ah ah ah ah $$$$$$$$$$
DEPD, a high resolution gene expression profiling technique capable of identifying new drug targets in the central nervous system.
Maelicke A, Lubbert H.
Biofrontera Pharmaceuticals AG, Hemmelrather Weg 201, D-51377 Leverkusen, Germany. maelicke@biofrontera.de
Digital expression pattern display (DEPD) is an open, automated, PCR-based system of gene expression profiling that is capable of resolving as many as 100,000 transcripts from a single brain tissue cDNA sample. It has a detection sensitivity of better than 1 in 750,000 and it can reliably detect differences in RNA expression levels of less than two-fold. Digital expression pattern display presently is the most sensitive and therefore the only expression profiling method available that is capable of monitoring, in a semi-quantitative fashion, the expression of even the rarest of transcripts found in human brain tissue. Biofrontera applies this proprietary technique, together with state-of-the-art bioinformatics, for the purposes of elucidating pathology pathways of major brain diseases, of analysing the target profiles of drugs presently applied or in development, and of identifying novel targets for drug action.
Biofrontera Pharmaceuticals GmbH Release: German Patent Office Has Issued Patent For DEPD(R)-Technology
The German patent office has awarded a patent for the core technology of Biofrontera Pharmaceuticals GmbH, Digital Expression Pattern Display (DEPD(R)). DEPD was developed by Biofrontera's founders at Novartis Pharma AG, Basel, Switzerland. Biofrontera Pharmaceuticals GmbH has received an exclusive licence for further development and application of DEPD.
red_tag_ed - You hit the nail right on the head.
Ann,also on the Janssen Collaboration with Biofrontera its on Alzheimers disease.Also another Note: Although the merger with Kiadis did not work out "for Now" Work between Biofrontera and Kiadis is on going and very strong.
Ann here is something else to think about - From the 8k filing -
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
The parties named in (1) and (2), (5) to (27) and Johnson Matthey Pharmaceuticals Materials Inc. (hereinafter referred to as Johnson Matthey) entered into (i) a "Shareholders' Agreement" dated 3 July 2003, (ii) in July 2003 into an "Amendment to Shareholders' Agreement dated 3 July 2003" and (iii) and an "Investment Agreement" dated 3 July 2003. The parties named in (1), (2) and (5) to (27) entered into (iv) an "Amendment to Investment Agreement dated 3 July 2003" dated 31 December 2003. In May 2004 the parties named in (3) and (4) acquired the shares of Johnson Matthey and took over its rights and obligations under the agreements named in (i), (ii) and (iii) and became party to the agreement named in (iv). The agreements named in (i) and (ii) are collectively referred to as the Shareholders' Agreement. The agreements named in (iii) and
(iv) are collectively referred to as the Investment Agreement.
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
and from the history file on the Biofrontera web site - The PharmEco agreement Plus Our ceo's address is listed as living in Ma. not Fl.This would suggest to me that Johnson Matthey Via PharmEco Via Richard Gaberil is working in some way with Biofrontera.
ann,
Did you know about Dr. Volker W.Bohnisch and his tie to "Boehringer Mannheim" {http://www.corporateinformation.com/cosearch.asp?terms=Boehringer+Mannheim+Biochemicals&search_b... and Dr. Bernd Wetzel tie to "Boehringer Ingelheim" {http://us.boehringer-ingelheim.com/}This will be very good for Dnap.
bio,if you been following this for 3 years and have not found a reason to stay and you are now looking for a reason than i would say to you there is no reason to give you that your EARS and eyes will accept.
Johnson Matthey Pharmaceuticals Materials Inc owns shares in Biofrontera
Wake up you slobs Johnson Matthey Pharmaceuticals Materials Inc is involved, via pharm-eco, via our ceo. If you did more DD you would have found this out. This is the last post
bifd
Johnson Matthey becomes your strategic partner in pharmaceutical product development and production.
As your strategic partner, Johnson Matthey helps you develop and produce the world's highest quality active pharmaceutical ingredients, meet tight production deadlines and speed new products to market.
We assign a highly trained technical team to guide and assist you. Your Johnson Matthey scientific team is experienced in:
Sophisticated process development
State-of-the-art analytical methodologies
Rigid process validation procedures
Responsive customer service
Strict regulatory compliance
Shorten the bridge from laboratory to the marketplace. Find out how you may benefit from a Johnson Matthey partnership. Please contact us for more details or Call (856) 384-7001 (800) 444-8544 (toll-free from USA only)
Production Capabilities
The Johnson Matthey team helps you meet your production requirements - and your deadlines, offering:
Wide reactor capacity range: from 5 to 2,000 gallons (22 - 7,500 litres)
Strict cGMP control standards for laboratory production volumes
Materials of construction either in glass-lined or hastalloy C reactors
Multiple stand-alone trains ensure full range of scale-up equipment
Hydrogenation capabilities to 100 psi
Particle-size reduction equipment
All products are handled in Class 100,000 contamination-control rooms with HEPA filtered-air-handling systems
Ample warehouse facilities serve our customers' growing needs
Unrivalled security and materials control
Adherence to FDA's current Good Manufacturing Practice (cGMP) requirements including filing a Drug Master File (DMF) with the FDA and managing a pre-approval inspection
International compliance filing
Strict compliance with DEA manufacturing requirements for Class I through Class V controlled substances
Service
We listen and guide you
A special Johnson Matthey team works with you each step of the way from raw materials to finished, tested product.
We advise you and we resolve difficult synthetic process routes. Perhaps most important, we help you reduce new product development time.
Process development expertise
Your Johnson Matthey team is staffed heavily with Ph.D. level chemists with broad experience in organic and organometallic chemistry. A highly skilled team of scientists from Johnson Matthey's Chemical Process Research and Development (CPR&D) group works with you every step of the way offering innovative solutions to difficult synthetic processes.
Johnson Matthey: the competitive edge
Your success-driven Johnson Matthey team helps you produce the industry's highest quality products and deliver them on schedule.
Here's Pharm-Eco web site take a look - http://www.pharmeco.com/
Biofrontera completes its technology platform and starts its first drug discovery collaboration with PharmEco Inc., Lexington, MA, USA This is from the Biofrontera web site.
>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
I told you all, our ceo and PharmEco, that he is co-owner of is involved with Dnap. And Johnson Matthey owns it all.